The Federal Trade Commission (FTC) has reached a multibillion-dollar settlement with CVS Caremark to lower prescription drug costs, a move estimated to save consumers $4.5 billion over the next 10 years. The agreement requires the pharmacy benefit manager (PBM) to pass rebate savings directly to patients rather than retaining them as profit, according to FTC officials.
How the CVS Caremark Settlement Changes Patient Costs
The FTC alleges that PBMs drove up medication prices by encouraging higher list prices to secure larger rebates from drug manufacturers. Under the new terms, these rebates—which previously benefited the PBM—will be passed to the patients. FTC Director of Competition Daniel Guarnera stated that many patients previously overpaid at the pharmacy counter because their costs were tied to these inflated list prices.
A critical component of the agreement is a price cap on insulin. Affected patients will see insulin costs capped at $25 per month, providing a concrete ceiling for one of the most volatile medication categories in the U.S. healthcare system.
Did you know? Pharmacy Benefit Managers (PBMs) act as the “middlemen” of the drug industry. They sit between insurance companies, pharmacies, and manufacturers to decide which drugs are covered and how much a patient pays.
The Market Power of the ‘Big Three’ PBMs
CVS Caremark is one of three dominant players in the industry. Together with Express Scripts and Optum Rx, these firms manage roughly 80% of all prescriptions filled in the United States. This concentration of power allows PBMs to dictate market terms to independent pharmacies.
Apollon Constantinides, owner of Lakeside Pharmacy and Compounding Lab in Forsyth County, describes this as an “overreach.” He notes that PBMs now exert significant control over what pharmacies can carry and how medications enter the market. Constantinides characterizes the leadership of these PBMs as “bean counters” focused on financial metrics rather than medical care.
Comparative FTC Actions Against PBMs
| PBM Entity | FTC Status | Key Outcome/Detail |
|---|---|---|
| CVS Caremark | Settled | $4.5B estimated savings; $25 insulin cap |
| Express Scripts | Settled | Settlement reached (details pending) |
| Optum Rx | Proposed | Settlement currently under consideration |
The ‘Rebate Trap’ and Drug Affordability
The FTC’s complaint describes the U.S. drug affordability crisis as a result of “manipulation of drug price competition for their own gain.” In a standard rebate model, a manufacturer sets a high list price. The PBM then negotiates a rebate from the manufacturer. If the PBM keeps that rebate, the patient—whose co-pay is often a percentage of the high list price—pays more out of pocket.
CVS Caremark defended the settlement in a statement to Channel 2 Action News, claiming the agreement “advances and reinforces the changes we have already put in place and ensures affordability for families and patients across the country.”
Pro Tip: If you are paying high out-of-pocket costs for prescriptions, ask your pharmacist if there are manufacturer coupons or if your insurance plan has updated its formulary based on new PBM regulations.
Frequently Asked Questions
What is a PBM?
A Pharmacy Benefit Manager is an intermediary that manages prescription drug programs for health insurers, pharmacy networks, and government programs.
How much will I save with the CVS Caremark settlement?
While individual savings vary, the FTC estimates a total of $4.5 billion in consumer savings over the next decade. Specifically, affected insulin users will have their costs capped at $25 per month.
Are other PBMs affected by this?
Yes. The FTC has already settled with Express Scripts and is considering a proposed settlement with Optum Rx. These three companies control about 80% of the U.S. prescription market.
Want to stay updated on healthcare costs and consumer rights? Subscribe to our daily newsletter or leave a comment below telling us how PBMs have affected your pharmacy experience.
Keep reading